n 20 mg + Ezetimibe 10 mg/day + Bempedoic acid 180 mg/day Alirocumab 150 mg every 2 weeks Evolocumab 140 mg just about every 2 weeks Rosuvastatin 50 mg/day (+ Ezetimibe 10 mg/day) + Alirocumab/Evolocumab/Inclisiran Atorvastatin 100 mg/day (+ Ezetimibe ten mg/day) + Alirocumab/Evolocumab/Inclisiran Simvastatin 200 mg/day (+ Ezetimibe ten mg/day) + Alirocumab/Evolocumab/InclisiranVery high threat 55 mg/dl (1.4 mmol/l) and reduction of baseline LDL-C 50 85 mg/dl ( 2.two mmol/l)Arch Med Sci six, October /M. Banach, P. Burchardt, K. Chlebus, P. Dobrowolski, D. Dudek, K. Dyrbu, M. Gsior, P. Jankowski, J. J iak, L. Klosiewicz-Latoszek, I. Kowalska, M. Malecki, A. Prejbisz, M. Rakowski, J. Rysz, B. Solnica, D. Sitkiewicz, G. Sygitowicz, G. Sypniewska, T. Tomasik, A. Windak, D. Zozuliska-Zi kiewicz, B. CybulskaTable XVIII. Cont. Danger group Higher danger LDL-C 70 mg/dl ( 1.8 mmol/l) and reduction of baseline LDL-C 50 non-HDL-C one hundred mg/dl ( two.five mmol/l) Therapy Intensive lipid-lowering therapy ( LDL-C reduction by 500 ) Atorvastatin 400 mg/day Rosuvastatin 200 mg/day Rosuvastatin 50 mg/day + Ezetimibe 10 mg/day Atorvastatin 100 mg/day + Ezetimibe ten mg/day Pitavastatin 4 mg + Ezetimibe 10 mg/day Simvastatin 200 mg/day + Ezetimibe ten mg/day Pravastatin 40 mg/day + Ezetimibe 10 mg/day Lovastatin 40 mg/day + Ezetimibe ten mg/day Fluvastatin 80 mg/day + Ezetimibe 10 mg/day Inclisiran 300 mg each 3/6 months Moderately intensive lipid-lowering therapy ( LDL-C reduction by 300 ) Rosuvastatin 50 mg/day Atorvastatin one hundred mg/day Pitavastatin four mg/day Simvastatin 200 mg/day Pravastatin 40 mg/day Lovastatin 40 mg/day Fluvastatin 80 mg/day Pitavastatin 1 mg + Ezetimibe ten mg/day Simvastatin 100 mg/day + Ezetimibe ten mg/day Pravastatin 20 mg/day + Ezetimibe ten mg/day Lovastatin 20 mg + Ezetimibe 10 mg/day Fluvastatin 40 mg + Ezetimibe ten mg/day Bempedoic acid 180 mg/day + Ezetimibe 10 mg/day Low-intensity lipid-lowering therapy ( LDL-C reduction by 30 ) Pitavastatin 1 mg/day Simvastatin 10 mg/day Pravastatin 100 mg/day Lovastatin 100 mg/day Fluvastatin 40 mg/day Ezetimibe 10 mg/day Bempedoic acid 180 mg/dayModerate threat 100 mg/dl ( 2.5 mmol/l) 130 mg/dl (3.4 mmol/l)Low threat 115 mg/dl ( 3 mmol/l)1 The advisable dose is 300 mg of inclisiran as a single subcutaneous BRD9 manufacturer injection administered: for the first time, once more following 3 months, after which just about every six months thereafter. 2as monotherapy or as a fixed dose mixture.to limitations regarding PCSK9 inhibitors, but give a clear recommendation for instant use of statin/ezetimibe mixture therapy in selected groups of individuals (similarly to lipid-lowering therapy) and indicate the must extend the therapeutic programme with PCSK9 inhibitors as quickly as you can, together with the possibility of quick inclusion for selected patient groups (i.e. with no the must wait 3-6 months, in accordance with current regulations). Moreover, in some sufferers with mixed hyperlipidaemia (dyslipidaemia or atherogenic dyslipidaemia), in order to optimise cardiovascular threat, a fibrate (fenofibrate) or possibly a formulation of unsaturated omega-3 acids should be utilized along with a statin or maybe a statin and ezetimibe. The usage of numerous agents with distinctive mechanisms of action could considerably raise therapy efficacy, and in some situations tends to make it attainable to use reduced doses, which in turn IP Synonyms results in a decrease risk of adverse reactions to these agents. At the identical time, it need to be emphasised that lipid problems are frequently accompanied by otherconditions